Andrea Mastropietro

Dr. Andrea Mastropietro

Sapienza University of Rome, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
Andrea MastropietroAndrea Mastropietro
Andrea Mastropietro
GPGiuseppe Pasculli
Giuseppe Pasculli
Jürgen BajorathJürgen Bajorath
Jürgen Bajorath

30 August 2022 in iScience
Verified
Journal Article
Open access
Andrea MastropietroAndrea Mastropietro
Andrea Mastropietro
GPGiuseppe Pasculli
Giuseppe Pasculli
CFChristian Feldmann
Christian Feldmann
RRRaquel Rodríguez-Pérez
Raquel Rodríguez-Pérez
Jürgen BajorathJürgen Bajorath
Jürgen Bajorath
Graph neural networks (GNNs) recursively propagate signals along the edges of an input graph, integrate node feature information with graph structure, and learn object representations. Like other deep neural network models, GNNs have notorious black box character. For GNNs, only few approaches are available to rationalize model decisions. We introduce EdgeSHAPer, a generally applicable method for explaining GNN-based models. The approach is devised to assess edge importance for predictions. Therefore, EdgeSHAPer makes use of the Shapley value concept from game theory. For proof-of-concept, EdgeSHAPer is applied to compound activity prediction, a central task in drug discovery. EdgeSHAPer’s edge centricity is relevant for molecular graphs where edges represent chemical bonds. Combined with feature mapping, EdgeSHAPer produces intuitive explanations for compound activity predictions. Compared to a popular node-centric and another edge-centric GNN explanation method, EdgeSHAPer reveals higher resolution in differentiating features determining predictions and identifies minimal pertinent positive feature sets.

10 July 2020
Verified
Book Chapter
Closed access
PDF file
AMAlessandro Maccagno
Alessandro Maccagno
Andrea MastropietroAndrea Mastropietro
Andrea Mastropietro
UMUmberto Mazziotta
Umberto Mazziotta
Michele ScarpinitiMichele Scarpiniti
Michele Scarpiniti
YLYong-Cheol Lee
Yong-Cheol Lee
AUAurelio Uncini
Aurelio Uncini

1 August 2023 in Bioinformatics
Verified
Journal Article
Open access
PDF file
Andrea MastropietroAndrea Mastropietro
Andrea Mastropietro
GCGianluca De Carlo
Gianluca De Carlo
AAAris Anagnostopoulos
Aris Anagnostopoulos
Motivation: Disease gene prioritization consists in identifying genes that are likely to be involved in the mechanisms of a given disease, providing a ranking of such genes. Recently, the research community has used computational methods to uncover unknown gene–disease associations; these methods range from combinatorial to machine learning-based approaches. In particular, during the last years, approaches based on deep learning have provided superior results compared to more traditional ones. Yet, the problem with these is their inherent black-box structure, which prevents interpretability. Results: We propose a new methodology for disease gene discovery, which leverages graph-structured data using graph neural networks (GNNs) along with an explainability phase for determining the ranking of candidate genes and understanding the model’s output. Our approach is based on a positive–unlabeled learning strategy, which outperforms existing gene discovery methods by exploiting GNNs in a non-black-box fashion. Our methodology is effective even in scenarios where a large number of associated genes need to be retrieved, in which gene prioritization methods often tend to lose their reliability. Availability and implementation: The source code of XGDAG is available on GitHub at: https://github.com/GiDeCarlo/XGDAG. The data underlying this article are available at: https://www.disgenet.org/, https://thebiogrid.org/, https://doi.org/10.1371/journal.pcbi.1004120.s003, and https://doi.org/10.1371/journal.pcbi.1004120.s004.

1 February 2023 in Bioinformatics
Verified
Journal Article
Open access
PDF file
PSPaola Stolfi
Paola Stolfi
Andrea MastropietroAndrea Mastropietro
Andrea Mastropietro
GPGiuseppe Pasculli
Giuseppe Pasculli
PTPaolo Tieri
Paolo Tieri
DVDavide Vergni
Davide Vergni
Gene-disease associations are fundamental for understanding disease etiology and developing effective interventions and treatments. Identifying genes not yet associated with a disease due to a lack of studies is a challenging task in which prioritization based on prior knowledge is an important element. The computational search for new candidate disease genes may be eased by positive-unlabeled learning, the machine learning setting in which only a subset of instances are labeled as positive while the rest of the data set is unlabeled. In this work, we propose a set of effective network-based features to be used in a novel Markov diffusion-based multi-class labeling strategy for putative disease gene discovery. The performances of the new labeling algorithm and the effectiveness of the proposed features have been tested on ten different disease data sets using three machine learning algorithms. The new features have been compared against classical topological and functional/ontological features and a set of network- and biological-derived features already used in gene discovery tasks. The predictive power of the integrated methodology in searching for new disease genes has been found to be competitive against state-of-the-art algorithms. The source code of NIAPU can be accessed at https://github.com/AndMastro/NIAPU. The source data used in this study are available online on the respective websites. Supplementary data are available at Bioinformatics online.

13 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ESEndrit Shahini
Endrit Shahini
GPGiuseppe Pasculli
Giuseppe Pasculli
Andrea MastropietroAndrea Mastropietro
Andrea Mastropietro
PSPaola Stolfi
Paola Stolfi
PTPaolo Tieri
Paolo Tieri
Gianluigi  GiannelliGianluigi Giannelli
Gianluigi Giannelli
Primary biliary cholangitis (PBC) is a chronic, cholestatic, immune-mediated, and progressive liver disorder. Treatment to preventing the disease from advancing into later and irreversible stages is still an unmet clinical need. Accordingly, we set up a drug repurposing framework to find potential therapeutic agents targeting relevant pathways derived from an expanded pool of genes involved in different stages of PBC. Starting with updated human protein–protein interaction data and genes specifically involved in the early and late stages of PBC, a network medicine approach was used to provide a PBC “proximity” or “involvement” gene ranking using network diffusion algorithms and machine learning models. The top genes in the proximity ranking, when combined with the original PBC-related genes, resulted in a final dataset of the genes most involved in PBC disease. Finally, a drug repurposing strategy was implemented by mining and utilizing dedicated drug–gene interaction and druggable genome information knowledge bases (e.g., the DrugBank repository). We identified several potential drug candidates interacting with PBC pathways after performing an over-representation analysis on our initial 1121-seed gene list and the resulting disease-associated (algorithm-obtained) genes. The mechanism and potential therapeutic applications of such drugs were then thoroughly discussed, with a particular emphasis on different stages of PBC disease. We found that interleukin/EGFR/TNF-alpha inhibitors, branched-chain amino acids, geldanamycin, tauroursodeoxycholic acid, genistein, antioestrogens, curcumin, antineovascularisation agents, enzyme/protease inhibitors, and antirheumatic agents are promising drugs targeting distinct stages of PBC. We developed robust and transparent selection mechanisms for prioritizing already approved medicinal products or investigational products for repurposing based on recognized unmet medical needs in PBC, as well as solid preliminary data to achieve this goal.